News

Medical advice motivates patients to reduce sodium intake

12.03.20151614

U.S. adults who received dietary medical advice were more likely to make changes to monitor or reduce their sodium consumption than adults who were not advised about their consumption, researchers reported in a new study.

Patients with high genetic risk for CHD benefit most from statin therapy

11.03.20152129

Adults with the highest genetic risk for CHD derived the greatest benefits from statin therapy, regardless of traditional risk factors, according to new findings.

CPAP therapy reduces risk for repeat revascularization after PCI

10.03.20151752

Untreated obstructive sleep apnea was associated with an increased risk for repeat revascularization after percutaneous coronary intervention, while continuous positive airway pressure therapy reduced that risk, according to study results.

Paroxetine improves cardiac function in mice after myocardial infarction

05.03.20151696

After noticing that paroxetine, a selective serotonin reuptake inhibitor normally used to treat depression, stopped the progression of heart failure in mice, researchers have concluded that the drug could be reclassified for use in humans, investigators wrote in Science Translational Medicine.

Coffee drinking linked to lower subclinical atherosclerosis

04.03.20152178

Light to moderate coffee drinking – less than 5 cups per day – is associated with decreased coronary artery calcium, and thus decreased risk of cardiovascular disease, according to an analysis of a large cohort published online March 2 in Heart.

Study: No benefit from anticoagulant use in Beh?et’s disease

03.03.20151667

Patients with vascular manifestations of Beh?et’s disease who received treatment with anticoagulants did not benefit from the therapy given in addition to immunosuppressant drugs, according to results from study of practices in Turkish rheumatology clinics.

Boehringer Ingelheim files BLA for antidote to dabigatran

02.03.20151718

Boehringer Ingelheim announced that it has submitted a biologics license application to the FDA requesting an accelerated approval pathway for idarucizumab, an antidote to dabigatran.